Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Tralokinumab
(D09979)		1件: Tralokinumab1件: Tralokinumab (D09979) 💬1件: IL13 💬8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬2件: 85, 97 💬
2Tralokinumab cohort 1
(D09979)		1件: Tralokinumab1件: Tralokinumab (D09979) 💬1件: IL13 💬8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬1件: 85 💬
3Tralokinumab cohort 2
(D09979)		1件: Tralokinumab1件: Tralokinumab (D09979) 💬1件: IL13 💬8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬1件: 85 💬
4Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
(D09979)		1件: Tralokinumab1件: Tralokinumab (D09979) 💬1件: IL13 💬8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬1件: 85 💬